Overcoming chemoresistance in osteosarcoma: the role of autophagy in cell death or survival following chemotherapy
Conference item
Rosa, G., Burczynska, B., Stordal, B. and Roberts, H. 2018. Overcoming chemoresistance in osteosarcoma: the role of autophagy in cell death or survival following chemotherapy. Research Degrees Students' Summer Conference. Middlesex University, London, UK 04 Sep 2018
| Title | Overcoming chemoresistance in osteosarcoma: the role of autophagy in cell death or survival following chemotherapy |
|---|---|
| Authors | Rosa, G., Burczynska, B., Stordal, B. and Roberts, H. |
| Abstract | Background: For the past 30 years, long-term survival rates in metastatic and recurrent osteosarcoma (OS) patients has remained unchanged. Drug resistance is thought to be the main cause and overcoming this phenomenon is a key step towards greater efficacy with OS therapy. Increasing evidence shows that autophagy, a 'self-degradation' pathway, can act as a protective mechanism to help cancer cells thrive under chemotherapeutic stress. The current study investigated the function of autophagy in two OS cell lines of varying metastatic capacity in response to two standard chemotherapy treatments, doxorubicin and cisplatin. Method: HOS-143B (highly metastatic) and MG-63 (less metastatic) cell lines were treated with doxorubicin (Dox) and cisplatin (Cis) for 48h (1). An acid phosphatase-based proliferation assay was used to calculate IC50s of each drug. Autophagy activation was determined based on the protein expression of p62 and autophagic flux (LC3-I/LC3-II protein conversion), analysed with Western blotting. Gene expression of MAPLC3B and p62/SQSTM1 was measured using RT-PCR. LC3-II punctate formation was detected using immunofluorescence. Results: Both drugs significantly induced autophagic flux in MG63 and HOS-143B cells as shown by increased LC3-I to LC3-II conversion, with Dox increasing LC3-II expression to a higher extent compared with Cis. Immunofluorescence of LC3-II punctate confirmed this pattern. Dox treatment was also associated with reduced p62/SQSTM1 protein, indicating greater autophagic clearance. MAPLC3B and p62/SQSTM1 gene expression was elevated in both Dox treated cell lines. Conclusion: In both highly metastatic HOS-143B cells and less metastatic MG63 cell line, dox treatment induces autophagy to a greater extent when compared with cis. It is envisaged that enhancing our knowledge on the role of autophagy in chemoresistance will help us to identify novel targets for osteosarcoma treatment. |
| Sustainable Development Goals | 3 Good health and well-being |
| Middlesex University Theme | Health & Wellbeing |
| Research Group | Biomarkers for Cancer group |
| Conference | Research Degrees Students' Summer Conference |
| Publication dates | |
| 04 Sep 2018 | |
| Publication process dates | |
| Deposited | 25 Jul 2022 |
| Accepted | 04 Aug 2018 |
| Output status | Published |
| Language | English |
Permalink -
https://repository.mdx.ac.uk/item/89xz1
54
total views0
total downloads5
views this month0
downloads this month
Export as
Related outputs
Breast cancer risk and prevention in 2024: An overview from the Breast Cancer UK ‐ Breast Cancer Prevention Conference
Stordal, B., Harvie, M., Antoniou, M.N., Bellingham, M., Chan, D.S.M., Darbre, P., Karlsson, O., Kortenkamp, A., Magee, P., Mandriota, S., Silva, E., Turner, J.E., Vandenberg, L.N. and Evans, D.G. 2024. Breast cancer risk and prevention in 2024: An overview from the Breast Cancer UK ‐ Breast Cancer Prevention Conference. Cancer Medicine. 13 (18). https://doi.org/10.1002/cam4.70255The efficacy of gemcitabine and docetaxel chemotherapy for the treatment of relapsed and refractory osteosarcoma: a systematic review and pre‐clinical study
Low, K., Foulkes, P., Hills, F., Roberts, H. and Stordal, B. 2024. The efficacy of gemcitabine and docetaxel chemotherapy for the treatment of relapsed and refractory osteosarcoma: a systematic review and pre‐clinical study. Cancer Medicine. 13 (18). https://doi.org/10.1002/cam4.70248Chromosomal copy number and mutational status are required to authenticate ovarian cancer cell lines as appropriate cell models
Stordal, B., Farrelly, A. and Hennessy, B. 2024. Chromosomal copy number and mutational status are required to authenticate ovarian cancer cell lines as appropriate cell models. Molecular Biology Reports. 51 (1). https://doi.org/10.1007/s11033-024-09747-4Ovarian cancer: identifying and managing familial and genetic risk
Slade, E., Berg, L., Dworzynski, K., Manchanda, R., Barber, V., Bowen, R., Brentnall, A., Cameron, A., Davies, D., Davies, M., Evans, D., Hayward, J., McCluggage, W., Miles, T., Monahan, K., Moses, D., Robb, F., Rosenthal, A., Side, L., Stanford, J., Stordal, B. and Tripathi, V. 2024. Ovarian cancer: identifying and managing familial and genetic risk. National Institute for Health and Care Excellence.Ovarian cancer: identifying and managing familial and genetic risk—summary of new NICE guidance
Slade, E., Berg, L., Dworzynski, K., Manchanda, R., Barber, V., Bowen, R., Brentnall, A., Cameron, A., Davies, D., Davies, M., Evans, D., Hayward, J., McCluggage, W., Miles, T., Monahan, K., Moses, D., Robb, F., Rosenthal, A., Side, L., Stanford, J., Stordal, B. and Tripathi, V. 2024. Ovarian cancer: identifying and managing familial and genetic risk—summary of new NICE guidance. British Medical Journal. 385. https://doi.org/10.1136/bmj.q807Identifying fibroblast growth factor receptor 3 as a mediator of periosteal osteochondral differentiation through the construction of microRNA-based interaction networks
Wells, L., Roberts, H., Luyten, F. and Roberts, S. 2023. Identifying fibroblast growth factor receptor 3 as a mediator of periosteal osteochondral differentiation through the construction of microRNA-based interaction networks. Biology. 12 (11). https://doi.org/10.3390/biology12111381A machine learning‑based image segmentation method to quantify in vitro osteoclast culture endpoints
Davies, B.K., Hibbert, A.P., Roberts, S.J., Roberts, H., Tickner, J.C., Holdsworth, G., Arnett, T.R. and Orriss, I.R. 2023. A machine learning‑based image segmentation method to quantify in vitro osteoclast culture endpoints. Calcified Tissue International and Musculoskeletal Research. 113 (4), p. 437–448.Wastewater monitoring for detection of public health markers during the COVID-19 pandemic: Near-source monitoring of schools in England over an academic year
Hassard, F., Vu, M., Rahimzadeh, S., Castro-Gutierrez, V., Stanton, I., Burczynska, B., Wildeboer, D., Baio, G., Brown, M., Garelick, H., Hofman, J., Kasprzyk-Hordern, B., Majeed, A., Priest, S., Denise, H., Khalifa, M., Bassano, I., Wade, M., Grimsley, J., Lundy, L., Singer, A. and Di Cesare, M. 2023. Wastewater monitoring for detection of public health markers during the COVID-19 pandemic: Near-source monitoring of schools in England over an academic year. PLoS ONE. 18 (5). https://doi.org/10.1371/journal.pone.0286259Awareness of ovarian cancer symptoms and risk factors in a young ethnically diverse British population
Radu, C., Matos de Melo Fernandes, N., Khalfe, S. and Stordal, B. 2023. Awareness of ovarian cancer symptoms and risk factors in a young ethnically diverse British population. Cancer Medicine. 12 (8), pp. 9879-9892. https://doi.org/10.1002/cam4.5670Establishment and characterization of single and triple‐agent resistant osteosarcoma cell lines
Low, K., Hills, F., Roberts, H. and Stordal, B. 2023. Establishment and characterization of single and triple‐agent resistant osteosarcoma cell lines. Advanced Biology. 7 (2). https://doi.org/10.1002/adbi.202200194Breastfeeding reduces the risk of breast cancer: a call for action in high-income countries with low rates of breastfeeding
Stordal, B. 2023. Breastfeeding reduces the risk of breast cancer: a call for action in high-income countries with low rates of breastfeeding. Cancer Medicine. 12 (4), pp. 4616-4625. https://doi.org/10.1002/cam4.5288Biomedical Science Exchanges at Middlesex University London
Stordal, B. 2019. Biomedical Science Exchanges at Middlesex University London. REALISE: Seminar on International Staff Mobility. Universities UK Boardroom, Woburn House, WC1H 9HQ, LondonBiomedical Science Exchanges
Stordal, B. 2018. Biomedical Science Exchanges. Middlesex University’s Erasmus Staff Training Week 2018. Middlesex University LondonBiomedical Science Exchanges
Stordal, B. 2018. Biomedical Science Exchanges. Middlesex University Staff Conference 2018: Learning through Change. Middlesex University London 27 Mar 2018Comparison of formative multiple choice questions using online platforms vs summative assessment: experience from an anatomy and physiology module
Stordal, B. 2015. Comparison of formative multiple choice questions using online platforms vs summative assessment: experience from an anatomy and physiology module. Middlesex University Annual Learning and Teaching Conference 2015: Revisiting Assessment. London, UK 13 Jul 2015ROR1-A novel biomarker for chemoresistance in ovarian cancer
Shafat, E., Hills, F. and Stordal, B. 2018. ROR1-A novel biomarker for chemoresistance in ovarian cancer. Research Degrees Students' Summer Conference. Middlesex University, London, UK 04 Sep 2018Optimisation of a selection strategy for drug resistance osteosarcoma cell lines
Low, K., Hills, F., Roberts, H. and Stordal, B. 2018. Optimisation of a selection strategy for drug resistance osteosarcoma cell lines. Research Degrees Students' Summer Conference. Middlesex University, London, UK 04 Sep 2018Mechanisms of apoptosis and autophagy in chemoresistant ovarian cancer cells
Bennacer, A., Roberts, H. and Stordal, B. 2018. Mechanisms of apoptosis and autophagy in chemoresistant ovarian cancer cells. Research Degrees Students' Summer Conference. Middlesex University, London, UK 04 Sep 2018Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer: Diagnostics guidance [DG34]
Nixon, F., Albrow, R., Donna, B., Kroese, D., Adair, E., Bagshaw, J., Carrol, E., Driskell, O., Edwards, S., Fleming, S., Gray, J., Halligan, S., Hitchman, J., Hyde, C., McGinley, P., Messenger, M., Moseley, A., Naylor, P., Neely, D., Rahman Haley, S., Richards, S., Sculpher, M., Stevenson, M., Summerton, N., Wierzbicki, A., Bramley, M., Graham, J., Pepper, L., Ryyan, D., Stordal, B., Van Mann, U. and Wardley, A. 2018. Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer: Diagnostics guidance [DG34]. NICE.Cross resistance between cisplatin and oxaliplatin in a low-level resistance lung cancer cell model
Stordal, B., Davey, M. and Davey, R. 2005. Cross resistance between cisplatin and oxaliplatin in a low-level resistance lung cancer cell model. 96th AACR Annual Meeting. Anaheim California 16 - 20 Apr 2005 American Association for Cancer Research. pp. 348-349Oxaliplatin and cisplatin cause similar chromosomal changes in H69 SCLC cells: linking changes in genotype to the resistant phenotype
Stordal, B., Peters, G., St. Heaps, L. and Davey, R. 2006. Oxaliplatin and cisplatin cause similar chromosomal changes in H69 SCLC cells: linking changes in genotype to the resistant phenotype. 97th AACR Annual Meeting. Washington D.C., USA 01 - 05 Apr 2006 American Association for Cancer Research. pp. 133BRCA1/2 mutation analysis in 43 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation
Stordal, B., Timms, K., Renuad, M., Thery, J., Farrelly, A., Williams, D., Potter, J., Tran, T., Korpanty, G., Cremona, M., Carey, M., Li, J., Li, Y., Aslan, O., O'Leary, J., Mills, G. and Hennessy, B. 2012. BRCA1/2 mutation analysis in 43 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation. 103rd Annual Meeting of the American Association for Cancer Research (AACR). Chicago 31 Mar - 04 Apr 2012 American Association for Cancer Research. https://doi.org/10.1158/1538-7445.AM2012-78A systematic approach to the study of cancer stem cells applied to ovarian cancer
Ffrench, B., Cooke, A., Stordal, B., O'Toole, S., Sheils, O., Gallagher, M. and O'Leary, J. 2012. A systematic approach to the study of cancer stem cells applied to ovarian cancer. 103rd Annual Meeting of the American Association for Cancer Research (ACCR). Chicago, USA 31 Mar - 04 Apr 2012 American Association for Cancer Research. https://doi.org/10.1158/1538-7445.AM2012-3382Overcoming chemoresistance in osteosarcoma: the role of autophagy in cell death or survival following chemotherapy
Rosa, G., Burczynska, B., Stordal, B. and Roberts, H. 2018. Overcoming chemoresistance in osteosarcoma: the role of autophagy in cell death or survival following chemotherapy. 2018 NCRI Cancer Conference. Glasgow, Scotland 04 - 06 Nov 2018ROR1- A biomarker for chemoresistance in ovarian cancer
Syed, E., Hills, F. and Stordal, B. 2018. ROR1- A biomarker for chemoresistance in ovarian cancer. 2018 NCRI Cancer Conference. Glasgow, Scotland 04 - 06 Nov 2018Optimisation of a selection strategy for drug resistance osteosarcoma cell lines
Low, K., Hills, F., Roberts, H. and Stordal, B. 2019. Optimisation of a selection strategy for drug resistance osteosarcoma cell lines. 2019 NCRI Cancer Conference. Glasgow, UK 03 - 05 Nov 2019The EMTactivator ZEB1 is unrelated to platinum drug resistance in ovarian cancer but predictive of survival
Rae, S., Keenan, J., Spillane, C., Blackshields, G., Madden, S. and Stordal, B. 2015. The EMTactivator ZEB1 is unrelated to platinum drug resistance in ovarian cancer but predictive of survival. 2015 NCRI Cancer Conference. Liverpool, UK 01 - 03 Nov 2015BRCA1 promoter methylation and clinical outcomes in epithelial ovarian cancer a pooled analysis of individual patient data
Kalachand, R., Stordal, B., Madden, S., Chandler, B., Cunningham, J., Goode, E., Ruscito, I., Braicu, E., Sehouli, J., Ignatov, A., Yu, H., Katsaros, D., Lu, L., Mills, G., Broaddus, R., Lu, K., Carey, M., Timms, K., Rzepecka, I., Kupryjanczyk, J., Swisher, E., Harrell, M., Agnew, K., O'Riain, C., O'Toole, S., O'Leary, J., Thomas, D., Chaudhry, P., Srinivasan, R. and Hennessy, B. 2019. BRCA1 promoter methylation and clinical outcomes in epithelial ovarian cancer a pooled analysis of individual patient data. Lorne Cancer Conference. Lorne, Victoria, Australia 14 - 16 Feb 2019Comparative selection strategies for development of platinum-drug resistant ovarian cancer cell lines
Busschots, S., Kalachand, R., O'Toole, S., O'Leary, J., Hennessy, B. and Stordal, B. 2017. Comparative selection strategies for development of platinum-drug resistant ovarian cancer cell lines. 12th International Symposium on Platinum Coordination Compounds in Cancer Chemotherapy. Sydney, Australia 10 - 14 Dec 2017PO-495 PI3K pathway upregulation mediates acquired resistance to platinum agents and polyadenoribose polymerase inhibitors (PARPi) in BRCA1-methylated ovarian cancer (OC)
Kalachand, R., Cremona, M., Farrelly, A., Eustace, A., Stordal, B. and Hennessy, B. 2018. PO-495 PI3K pathway upregulation mediates acquired resistance to platinum agents and polyadenoribose polymerase inhibitors (PARPi) in BRCA1-methylated ovarian cancer (OC). EACR25: The 25th Biennial Congress of the European Association for Cancer Research. Amsterdam, Netherlands 30 Jun - 03 Jul 2018Monitoring occurrence of SARS-CoV-2 in school populations: A wastewater-based approach
Castro-Gutierrez, V., Hassard, F., Vu, M., Leitao, R., Burczynska, B., Wildeboer, D., Stanton, I., Rahimzadeh, S., Baio, G., Garelick, H., Hofman, J., Kasprzyk-Hordern, B., Kwiatkowska, R., Majeed, A., Priest, S., Grimsley, J., Lundy, L., Singer, A. and Di Cesare, M. 2022. Monitoring occurrence of SARS-CoV-2 in school populations: A wastewater-based approach. PLoS ONE. 17 (6). https://doi.org/10.1371/journal.pone.0270168The role of autophagy in canine osteosarcoma chemoresistance and metastasis
Kulatheepan, Y., Baines, S., Meeson, R. and Roberts, H. 2022. The role of autophagy in canine osteosarcoma chemoresistance and metastasis. 26th Annual Technological Advances in Science, Medicine and Engineering Conference 2022. Virtual 27 - 28 Aug 2022ATR inhibition increases sensitivity of a highly aggressive osteosarcoma cell line to cisplatin treatment
Pereira, J., Roberts, S. and Roberts, H. 2022. ATR inhibition increases sensitivity of a highly aggressive osteosarcoma cell line to cisplatin treatment. Research Students' Summer Conference. Middlesex University, Lonon, UK 22 - 23 Jun 2022Migratory bodies express markers of tumour initiating cells and may represent an early stage of osteosarcoma sarcosphere initiation and metastasis
Paternina Martinez, D., Roberts, S. and Roberts, H. 2022. Migratory bodies express markers of tumour initiating cells and may represent an early stage of osteosarcoma sarcosphere initiation and metastasis. Research Students' Summer Conference. Middlesex University, Lonon, UK 22 - 23 Jun 2022CRISPR/Cas9-mediated ATG7 knockout results in enhanced osteosarcoma chemosensitivity
Pears, A. and Roberts, H. 2022. CRISPR/Cas9-mediated ATG7 knockout results in enhanced osteosarcoma chemosensitivity. Bone Research Society Annual Conference. Manchester Metropolitan University, Manchester, UK 06 - 08 Jul 2022ATR inhibition increases sensitivity of a highly aggressive osteosarcoma cell line to cisplatin treatment
Pereira, J., Roberts, S. and Roberts, H. 2022. ATR inhibition increases sensitivity of a highly aggressive osteosarcoma cell line to cisplatin treatment. Bone Research Society Annual Conference. Manchester Metropolitan University, Manchester, UK 06 - 08 Jul 2022Migratory bodies express markers of tumour initiating cells and may represent an early stage of osteosarcoma sarcosphere initiation and metastasis
Paternina Martinez, D., Roberts, S. and Roberts, H. 2022. Migratory bodies express markers of tumour initiating cells and may represent an early stage of osteosarcoma sarcosphere initiation and metastasis. Bone Research Society Annual Conference. Manchester Metropolitan University, Manchester, UK 06 - 08 Jul 2022Intentionality for inclusivity - the journey at Middlesex University
Roberts, H., Punev, I., Allardyce, D., Kyprianou, A., Appiah, S., Megeney, A., Calin, A., Gallacher, D. and Mill, R. 2022. Intentionality for inclusivity - the journey at Middlesex University. McGraw Hill.Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer [Review - Intervention]
Patel, A., Kalachand, R., Busschots, S., Doherty, B., Kapros, E., Lawlor, D., Hall, N. and Stordal, B. 2022. Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer [Review - Intervention]. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.CD008766.pub3The EMT-activator ZEB1 is unrelated to platinum drug resistance in ovarian cancer but is predictive of survival
Rae, S., Spillane, C., Blackshields, G., Madden, S., Keenan, J. and Stordal, B. 2022. The EMT-activator ZEB1 is unrelated to platinum drug resistance in ovarian cancer but is predictive of survival. Human Cell. 35 (5), pp. 1547-1559. https://doi.org/10.1007/s13577-022-00744-y